Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2018 Mar 5:2018:7092414.
doi: 10.1155/2018/7092414. eCollection 2018.

Effect of Stains on LDL Reduction and Liver Safety: A Systematic Review and Meta-Analysis

Xiao Liang  1 , Qin He  1 , Qinghua Zhao  1
Affiliations
Meta-Analysis

Effect of Stains on LDL Reduction and Liver Safety: A Systematic Review and Meta-Analysis

Xiao Liang et al. Biomed Res Int. .

Abstract

Background and aim: Statin is a class of medications used to decrease low-density lipoprotein cholesterol level to prevent cardiovascular disease. However, the risk of hepatic damage caused by statin therapy is still controversial. We conducted a systematic review and meta-analysis summarizing the existing evidence of the effect of statin therapy on incidence of liver injury to clarify whether statin therapy could lead to liver function test abnormalities.

Methods: We searched the Cochrane Library, PubMed, and Embase database for the relevant studies update till Jan. 2017 regarding statin therapy and liver injury. Two researchers screened the literature independently by the selection and exclusion criteria. Odds ratios (ORs) and 95% confidence intervals (CIs) were pooled using random effects models, and subgroup analyses were performed by study characteristics. This meta-analysis was performed by STATA 13.1 software.

Results: Analyses were based on 74,078 individuals from 16 studies. The summary OR of statin therapy was 1.18 (95% CI: 1.01-1.39, p = 0.04; I2 = 0.0%) for liver injury. Subgroup analysis indicated that fluvastatin increased the risk of liver injury significantly (OR, 3.50; 95% CI: 1.07-11.53, p = 0.039; I2 = 0.0%) and dose over 40 mg/daily had an unfavorable effect on the liver damage (OR, 3.62; 95% CI: 1.52-8.65, p = 0.004; I2 = 0.0%). The sensitivity analysis indicated that the results were robust.

Conclusion: Our findings confirm that statin therapy substantially increases the risk of liver injury, especially using fluvastatin over 40 mg/d.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flowchart of study selection.
Figure 2
Figure 2
Meta-analysis of the association between statin therapy and incidence of liver injury. The area of each square is proportional to the inverse of the variance of the log relative risks. Horizontal lines represent the 95% confidence intervals (CIs). Diamonds represent pooled estimates from an inverse variance-weighted random effects model. OR = odds ratio.
Figure 3
Figure 3
Figure 4
Figure 4
Funnel plot for statin therapy and incidence of liver injury.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Baigent C., Keech A., Kearney P. M. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. The Lancet. 2005;366(9493):1267–1278. doi: 10.1016/s0140-6736(05)67394-1. - DOI - PubMed
    1. Smith S. C., Jr., Benjamin E. J., Bonow R. O., Braun L. T., Creager M. A., Franklin B. A., et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the american heart association and american college of cardiology foundation endorsed by the world heart federation and the preventive cardiovascular nurses association. Journal of the American College of Cardiology. 2011;58(23):2432–2446. doi: 10.1016/j.jacc.2011.10.824. - DOI - PubMed
    1. Auer J., Berent R., Weber T., Eber B. Clinical significance of pleiotropic effects of statins: Lipid reduction and beyond. Current Medicinal Chemistry. 2002;9(20):1831–1850. doi: 10.2174/0929867023369024. - DOI - PubMed
    1. Chalasani N. Statins and hepatotoxicity: focus on patients with fatty liver. Hepatology. 2005;41(4):690–695. doi: 10.1002/hep.20671. - DOI - PubMed
    1. Clarke A., Mills P. R. Atorvastatin associated liver disease. Digestive and Liver Disease. 2006;38(10):772–777. doi: 10.1016/j.dld.2006.04.013. - DOI - PubMed

Substances

LinkOut - more resources